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Immunodeficiency Syndromes
Introduction
Common variable immunodeficiency (CVID) is the most
prevalent form of symptomatic primary antibody deficiency.1
It is defined by: 1) a marked decrease in serum IgG and IgA or
IgM of at least 2 standard deviations (SD) below the mean for
age; 2) absent isohemagglutinins and/or poor response to vac-
cines; 3) onset of immune deficiency after two years of age;
and 4) exclusion of other defined causes of hypogammaglob-
ulinemia.1 Patients with CVID suffer from recurrent infections
and non-infectious complications (autoimmune cytopenia,
polyclonal lymphocytic proliferation and persistent unex-
plained enteropathy), of which the latter are associated with
increased mortality.2,3 By definition, CVID excludes a group of
patients with idiopathic primary hypogammaglobulinemia,
who suffer from hypogammaglobulinemia but do not fulfill
CVID diagnostic criteria with respect to a reduction of two
immunoglobulin isotypes and/or a reduced response to vacci-
nation. According to the CVID diagnostic classification of the
European Society for Immunodeficiency Diseases,4 some of
these patients with idiopathic primary hypogammaglobuline-
mia (further referred to as IPH) can be classified as “possible”
CVID, and in the ESID database of primary immunodeficien-
cies they are classified as “other hypogammaglobulinemias”.
Remarkably, according to the primary immunodeficiency
classification of the International Union of Immunological
Societies (IUIS) these patients cannot be sufficiently classified
within any of the subcategories of “Predominantly Antibody
Deficiency”.5 In comparison, the International Classification
of Diseases v10 (ICD10),6 classifies IPH as “hypogammaglob-
ulinemia not otherwise specified” with the same ICD10 code
as CVID. Patients with IPH are regularly encountered in clin-
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Patients with hypogammaglobulinemia who do not fulfill all the classical diagnostic criteria for common variable
immunodeficiency (reduction of two immunoglobulin isotypes and a reduced response to vaccination) constitute
a diagnostic and therapeutic dilemma, because information concerning the clinical and immunological character-
istics of these patients with idiopathic primary hypogammaglobulinemia is not available. In 44 common variable
immunodeficiency and 21 idiopathic primary hypogammaglobulinemia patients we determined the clinical phe-
notypes and performed flow cytometric immunophenotyping to assess the pathophysiological B-cell patterns and
memory B-cell subset counts. Age-matched B-cell subset reference values of 130 healthy donors were generated.
Severe pneumonia and bronchiectasis occurred at similar frequencies in idiopathic primary hypogammaglobuline-
mia and common variable immunodeficiency. Although IgG levels were only moderately reduced compared to
common variable immunodeficiency, 12 of 21 idiopathic primary hypogammaglobulinemia patients required
immunoglobulin replacement. Non-infectious disease-related clinical phenotypes (autoimmune cytopenia, poly-
clonal lymphocytic proliferation and persistent unexplained enteropathy) were exclusively observed in common
variable immunodeficiency and were associated with early peripheral B-cell maturation defects or B-cell survival
defects. T-cell dependent memory B-cell formation was more severely affected in common variable immunodefi-
ciency. Furthermore, 14 of 21 idiopathic primary hypogammaglobulinemia patients showed normal peripheral B-
cell subset counts, suggestive for a plasma cell defect. In conclusion, idiopathic primary hypogammaglobulinemia
patients who do not fulfill all diagnostic criteria of common variable immunodeficiency have moderately
decreased immunoglobulin levels and often a normal peripheral B-cell subset distribution, but still suffer from seri-
ous infectious complications.
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ABSTRACT
ical practice, but information concerning the prevalence
and the clinical and immunological characteristics is not
available. It is important to obtain insight into the frequen-
cy and severity of the clinical complications of IPH, to clar-
ify whether IPH is a clinically relevant antibody deficien-
cy, and to develop appropriate treatment strategies. In
addition, analysis of immunological parameters will
enable the comparison of pathophysiological aspects of
IPH and CVID. 
Therefore, we aimed to determine the position of IPH in
the spectrum of idiopathic antibody deficiencies through
clinical and immunological comparison with CVID. First,
we recorded the patients with the clinical phenotypes as
established by Chapel et al.2,7 In addition, we performed
flow cytometric immunophenotyping in order to analyze
T-cell dependent and independent memory B-cell subset
counts8 and blood B-cell patterns, which are associated
with differences in pathophysiological background.9
Methods
Patients
Peripheral blood samples and clinical data were collected for 44
CVID patients and 21 IPH patients. IPH was diagnosed if patients
had a reduction of IgG at least 2 SD below the mean for age, an
onset of the immunodeficiency after two years of age, exclusion
of defined causes of hypogammaglobulinemia and if they did not
fulfill the CVID diagnostic criteria with respect to a reduction of
two immunoglobulin isotypes and/or a reduced response to vacci-
nation. The group of CVID patients includes the 37 patients who
were reported in our original description of the B-cell patterns.9 In
addition, we collected blood from 130 healthy age-matched con-
trols and 26 cord blood samples. This study was approved by the
Medical Ethics Committee of the Erasmus MC.
Clinical phenotyping
Clinical data were collected from all IPH and CVID patients to
record their clinical phenotypes as previously described by Chapel
et al.2,5 These phenotypes are: 1) no disease-related complications
(infections only); 2) autoimmune cytopenias; 3) polyclonal lym-
phoproliferation (granuloma/LIP/persistent unexplained lympa-
denopathy); and 4) unexplained persistent enteropathy. In addi-
tion, data were collected concerning the frequency and severity of
infections and modes of treatment. Pneumococcal polysaccharide
vaccination responses were interpreted according to Borgers et al.10
as an adequate response to half of the measured pneumococcal
serotypes. 
Flow cytometric analysis and assignment 
of B-cell patterns
Six-color flow cytometric immunophenotyping of peripheral
blood was performed on a CantoII (BD Biosiences) and data were
analyzed using FACS Diva software (BD Biosiences). The follow-
ing monoclonal antibodies were used: CD19-PerCP-Cy5.5, CD19-
PE-Cy7, CD19-APC (all SJ25C1), CD5-APC ( L17F12 ), CD45-
PerCP (2D1), CD19-APC (SJ25C1), CD38-PE, CD38-APC and
CD38-PE-Cy7 ( HB7),  CD27-APC (L128), CD3-PerCP-Cy5.5
(SK7) and CD8-APC-Cy7 (SK1) (all from BD Biosciences), poly-
clonal IgD-FITC, IgD-PE and IgM-PE  (all from Southern
Biotechnologies), polyclonal IgG-FITC (Kallestad), IgA-FITC and
IgA-PE (IS11-8E10;  Miltenyl Biotech), CD24-FITC ( gran-B-ly-1;
Sanquin), CD21-PE ( LB21; Serotech), CD45RO-FITC ( UCHL1;
DAKO), CD4-PC7 (SFCI12T4D11)  and CD45-RA-RD1 (2H4; all
from Beckman Coulter). The cell counts of the peripheral B-cell
subsets (transitional B cells, naive mature B cells, and six memory
B-cell subsets) were compared to age-matched healthy controls. A
decrease or increase of a B-cell subset was defined as a value
below the 5th or above the 95th percentile. B-cell patterns were
determined as described previously9 and are summarized together
with their pathophysiological background in Table 1. 
Statistical analysis
Statistical analysis was performed with Graphpad prism 5.0
software (Graphpad Software, San Diego, CA, USA). The Mann-
Whitney test was used to compare continuous variables between
two groups. The non-parametric Kruskal-Wallis rank sum test was
used to compare multiple groups with continuous outcomes, fol-
lowed by pair-wise Mann-Whitney tests if the former indicated
significant differences. For categorical variables, the c2 was used or
Fisher’s exact test if required. Statistical significance was set at
two-sided P<0.05.
Results
Patients’ characteristics
This study involved 44 CVID patients (mean age 32
years, range 6-77 years) and 21 patients with IPH (mean
age 27 years, range 4-74). Age and gender distribution was
comparable between both groups. In the CVID group, 2 of
44 patients were from consanguineous families, and in 10
of 4 patients, the family history was positive for
hypogammaglobulinemia and/or IgA deficiency, com-
pared to one of 21 and 6 of 21 in IPH, respectively.  
Details regarding immunoglobulin levels, response to
immunization and infectious clinical complications of IPH
patients are provided in Table 2. All IPH patients showed
reduced serum IgG levels, but did not fulfill the diagnostic
criteria for CVID due to: adequate response to immuniza-
tion (n=7), normal levels of IgA and IgM (n=3) or both
(n=7) (Table 2). Four patients had normal levels of both
IgA and IgM (Table 2; patients 15-18), but vaccination data
were not available. The median IgG levels at diagnosis
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Table 1. B-cell patterns associated with different pathophysiological backgrounds in CVID.9
B-cell pattern Corresponding B-cell immunophenotype Pathophysiological background 
1 Reduction of transitional B cells and CD27+IgD- memory B cells Defect in B-cell production and germinal center
2 Normal transitional B cells and a reduction of naive mature, Defect in early B-cell maturation or survival
CD27+IgD+IgM+ and CD27+IgD- memory B cells
3 Reduction of CD27+IgD+IgM+ and CD27+IgD- memory B cells Defect in B-cell activation and proliferation
4 Isolated reduction CD27+IgD- memory B cells Defect in germinal center function
5 Normal CD27+IgD+IgM+ and CD27+IgD- memory B cells Post germinal center defect
Reduction: < 5th percentile of age-matched controls; normal: >5th percentile of age-matched controls.
were lower in patients with CVID (3.0 g/L, range 0-5.7)
compared to IPH (4.9 g/L, range 3.6-6.6) (Figure 1A).
Considering the IgG subclass levels, most patients had
IgG1 levels just below the normal range, with IgG2, IgG3
and IgG4 levels in the (lower) normal range (Table 1). In 6
patients, IgG subclasses were in the (lower) normal range
in the presence of a decreased total IgG. In addition, IgM
and IgA levels were lower in CVID, which was an expect-
ed finding because of the clinical definition of CVID and
IPH. 
Clinical phenotypes in CVID and IPH
All patients with CVID and IPH suffered from recurrent
upper respiratory tract infections. For IPH, the infectious
complications are summarized in Table 2. Many IPH
patients suffer from severe pneumonia (one or more
episodes with hospital admission) and bronchiectasis.
These complications were present in a similar frequency
compared to CVID patients (50% vs. 48% and 24% vs.
27%, respectively).  
Specific non-infectious disease-related clinical pheno-
types (autoimmune cytopenia, polyclonal lymphocytic
proliferation and persistent unexplained enteropathy) are
associated with an increased mortality in patients with
CVID.2,3 In our cohort, 79% of the CVID patients suffered
from infections only, with the remaining 21% experienc-
ing one or more disease-related non-infectious clinical
Table 2. Clinical characteristics of patients with idiopathic primary hypogammaglobulinemia.
Patient  Age in Gender IgA# IgM# IgG# IgG1 IgG2 IgG3 IgG4 Response to  Bronchi- History of Other Other Immuno- Prophylactic
n. years #& #& #& #& pneumococcal ectasis on severe pulmonary serious or globulin antibiotics
polysaccharide HRCT pneumonia diagnosis frequent replacement
immunization** thorax infections$
1 11 M 0.3 0.5 5.0 3.65 1.36 0.15 0.1 normal no no no no no
2 9 M 0.2 0.6 4.3 3.66 0.64 0.23 0.15 normal no no ENT yes no
3 18 M 0.5 0.6 4.1 3.27 0.5 0.7 0.09 normal no yes ENT yes no
4 47 F 0.2 0.3 5.7 ND ND ND ND normal no no no no yes
5 47 M 1.2 0.3 5.1 3.29 1.63 0.17 0.2 normal no no no no no
6 10 F 0.3 0.3 4.9 3.94 0.82 0.19 0.17 normal no no asthma ENT yes no
7 4 F 0.4 0.3 4.7 3.8 0.63 0.15 0.08 normal no no no yes no
8 22 F 0.7 0.4 5.0 4.09 1.29 0.41 0.09 normal no yes meningitis no yes
9 74 F 0.9 0.5 4.4 ND ND ND ND normal no yes COPD no yes no
10 14 M 1.5 0.8 4.7 2.11 1.31 0.46 0.05 normal yes no asthma molluscae  yes no
11 9 F 0.6 0.6 5.2 3.7 1.39 0.28 0.33 normal yes yes no yes no
12 60 M 0.9 1.1 4.9 4.36 1.57 0.22 0.68 normal yes yes ENT no yes
13 16 F 1.7 1.2 6.1 4.15 2.06 0.18 0.35 normal no yes asthma no no no
14 9 F 0.4 1.0 4.5 3.57 0.78 0.33 0.05 normal no no asthma ENT yes no
15 44 F 1.2 0.4 5.5 3.42 1.38 0.21 0.45 unknown no no skin no no
16 6 M 0.7 0.9 4.3 2.8 0.95 0.11 0.06 unknown no no skin no no
17 18 M 0.7 1.6 5.6 4.2 1.39 0.55 0.05 unknown yes yes asthma no yes yes
18 32 F 1.6 2.1 6.6 3.29 0.95 0.39 0.06 unknown yes yes no  yes yes
19 10 F 1.0 0.5 4.0 4.76 1.67 0.29 0.3 abnormal no yes no yes no
20 59 F 1.6 0.8 6.1 3.76 3.16 0.32 0.31 abnormal no yes no yes no
21 57 M 1.3 0.4 6.0 ND ND ND ND abnormal no no no no yes
#Bold values are decreased levels (in g/L) compared to age-specific normal values (Online Supplementary Table S1). &IgG subclasses were sometimes performed at different time points to IgG, IgA
and IgM levels. **Response to pneumococcal polysaccharides was interpreted according to Borgers et al.8 $All patients experienced recurrent upper respiratory tract infections. ENT: frequent and seri-
ous Ear Nose and Throat infections (all these patients got multiple ENT operations); Asthma: asthmatic bronchitis, COPD: chronic obstructive pulmonary disease; ND: not determined 
Figure 1. Immunoglobulin levels and clinical phenotypes in CVID and
IPH. (A) Immunoglobulin levels at diagnosis in CVID and IPH. Groups
are compared with the Mann Whitney test. Significant values are
indicated. **** P<0.0001, *** P≤0.0005 (B) Clinical phenotypes
according to Chapel et al.7,14
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complications (Figure 1B). In contrast, all IPH patients suf-
fered only from infections. Therefore, non-infectious dis-
ease-related complications were observed exclusively in
CVID (P=0.02). 
Treatment
All CVID patients were treated with immunoglobulin
replacement therapy. Of the IPH patients, 12 of 21 (57%)
received immunoglobulin replacement (sometimes in
G. Driessen et al.
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Figure 2. Naive and memory B-cell subsets in normal controls. (A) Overview and definition of peripheral B-cell subsets. (B) Normal values of
transitional and naive B cells. (C) Normal values of memory B-cell subsets. Gray bars represent absolute counts and open bars proportions of
CD19+ cells. Bars indicate median with 25 and 75 percentiles. Whiskers represent 5th and 95th percentiles. (D) Relative distribution of memory
B-cell subsets per age category. 
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combination with prophylactic antibiotics). Of the
remaining 9 patients, 3 were treated with prophylactic
antibiotics and 6 received antibiotics during infectious
episodes as the only mode of treatment. 
B-cell subsets in healthy controls
In order to detect abnormalities in peripheral B-cell sub-
set distribution in patients, we generated age-related nor-
mal values of all B-cell subsets in a cohort of 130 healthy
controls (Figure 2A-D, Table 3). Absolute numbers of tran-
sitional B cells and naive mature B cells directly increase
after birth and decrease after the age of two years. The fre-
quency of transitional B cells decreases over time, while
the frequency of naive B cells remains stable (Figure 2B). 
The human memory B-cell compartment consists of six
subsets.8 CD27+IgD+IgM+ natural effector B cells are the
only memory subset that constitutes a considerable part of
the B-cell compartment in cord blood (Figure 2C).
Absolute counts of natural effectors increase after birth to
show a decline from 2-5 years. In contrast to absolute
counts, the proportion of natural effector B cells gradually
increases over time and form the largest proportion of
memory B cells within the memory B-cell compartment.
CD27- switched (IgA and IgG) memory B cells are present
at birth in very small amounts and reach maximum values
at 2-5 years, after which they decline to values just above
those in cord blood (Figure 2C and D). CD27+IgM+IgD-
(IgM-only) memory B cells and CD27+ switched (IgA+ and
IgG+) memory B cells are hardly present in cord blood, but
increase rapidly after birth to absolute counts that remain
stable over all age groups until adulthood. The relative
proportions of these CD27+ memory B-cell subsets show
an impressive increase over time (Figure 2D), which main-
ly reflects the declining absolute number of transitional
and naive mature B cells. 
Peripheral B-cell subset patterns are different 
in CVID and IPH
CVID patients can display one of five distinct B-cell pat-
terns.9 The patterns are based on the composition of the
peripheral B-cell compartment and the replication history
and somatic hypermutation frequency of the individual B-
cell subsets and are indicative for the pathophysiological
background of the antibody deficiency.9 The B-cell pat-
terns can be easily determined by flow cytometry. Our
earlier detailed molecular assays on sorted peripheral B-
cell subsets were used to characterize the patterns, but are
not used to define the pattern in individual patients. 
The five B-cell patterns with their corresponding patho-
physiological background are summarized in Table 1. The
distribution of B-cell patterns was different between
CVID and IPH (Figure 3A; P=0.003). B-cell patterns 1 and
2, which reflect B-cell production or early peripheral B-cell
maturation/survival defects, were exclusively present in
CVID (9 of 44 and 4 of 44, respectively) and not in IPH. B-
cell patterns 3 and 4, which are associated with B-cell acti-
vation, proliferation and germinal center (GC) defects,
were more common in CVID (12 of 44 and 10 of 44,
respectively) as compared to IPH (3 of 21 and 4 of 21,
respectively). In contrast, most IPH patients showed a nor-
mal peripheral B-cell subset distributions (B-cell pattern 5,
14 of 21), which is higher in frequency than CVID (9 of
44). The differences in B-cell patterns between CVID and
IPH patients were reminiscent of the differences in clinical
phenotypes: CVID patients with non-infectious complica-
tions predominantly displayed B-cell patterns 1 and 2
(Figure 3; P=0.003). 
Memory B-cell subsets are more severely affected
in CVID than in IPH patients
Data of memory B-cell subsets of CVID and IPH
patients were compared to age-matched controls and the
proportion of patients with normal (>5th percentile of age-
matched normal controls) and reduced (<5th percentile)
memory B-cell subset size was determined (cut-off values
are summarized in Table 3). The results are shown in
Figure 4. The T-cell independent CD27-IgA+ memory B-
cell subset was normal in the majority of CVID and IPH
patients. In CVID, four memory B-cell subsets were more
frequently reduced compared to IPH. T-cell dependent
Idiopathic primary hypogammaglobulinemia
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Figure 3. Pathophysiological B-cell patterns in CVID and IPH and rela-
tion to clinical phenotypes. (A) Comparison of B-cell patterns between
CVID (n=44) and IPH (n=21). B-cell patterns 1 and 2 are exclusively
observed in CVID (P=0.02). (B) B-cell patterns and clinical phenotypes
in CVID (n=44). Non-infectious complications (auto-immunity and
polyclonal lymphocytic proliferation) were more often observed in B-
cell pattern 1-2 compared to B-cell pattern 3-5 (P=0.003).  
Figure 4. Memory B-cell subsets in CVID and IPH. The proportion of
patients with normal memory B-cell subset size (>5th percentile of
age-matched normal controls) is depicted. Data of CVID and IPH
were compared with Fisher’s exact test. *P<0.05. 
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class switched CD27+IgA+ and CD27+IgG+ memory B cells
showed the most significant difference between the
groups. In line with these findings, 19 of 21 (90%) IPH
patients could be classified as smB+ (CD27+IgD- B cells
>2% of B cells) according to the EUROclass CVID classifi-
cation11 and only 2 of 21 (10%) as smB- (CD27+IgD- B cells
≤ 2% of B cells), whereas in CVID, 25 of 44 (57%) patients
were smB- and 19 of 44 smB+ (43%). In conclusion, mem-
ory B-cell formation was more severely affected in CVID
compared to IPH, primarily affecting GC-dependent
memory B-cell subsets. 
Discussion 
This study describes the clinical and immunological
characteristics of a group of patients with idiopathic pri-
mary hypogammaglobulinemia who do not fulfill the cri-
teria for CVID with respect to a reduction of two
immunoglobulin isotypes and/or an impaired response to
vaccination. These IPH patients have not yet been well
described in the literature and cannot be sufficiently clas-
sified within the current PID diagnostic classification sys-
tem.4 It has been previously shown that some “CVID”
patients have the ability to respond to vaccination,12,13 so
these patients might show similarities to some of the IPH
patients described in this present study. Our data raise the
question as to whether an impaired response to vaccina-
tion should be used for the diagnosis of CVID, especially
since solid criteria for the interpretation of vaccination
responses are lacking.
Important differences were observed between IPH and
CVID in clinical phenotypes, pathophysiological B-cell
pattern and memory B-cell subset sizes, but similarities
were also seen with respect to infectious complications.
IPH patients have less severe hypogammaglobulinemia
compared to CVID, but most patients with IPH still suf-
fered from recurrent or serious infections. There was no
significant difference in the occurrence of severe pneumo-
nia and bronchiectasis to patients with CVID and more
than half of the patients with IPH required immunoglobu-
lin replacement. These data support the idea that IPH is a
clinically relevant antibody deficiency. In contrast to
CVID, several IPH patients were in good clinical condition
without immunoglobulin replacement or antibiotic pro-
phylaxis. Apparently, the specific antibody production in
these patients was sufficient to prevent the occurrence of
severe or frequent infections. Long-term follow-up studies
are needed to examine which IPH patients require
immunoglobulin replacement and/or antibiotic prophy-
laxis, and to monitor whether IPH can develop into a full
CVID phenotype over time. 
Over recent years, Chapel et al. have described the dif-
ferent clinical phenotypes of CVID patients2,14 and con-
vincingly showed that non-infectious clinical complica-
tions (autoimmune cytopenia, polyclonal lymphocytic
proliferation and persistent unexplained enteropathy) are
associated with increased mortality compared to patients
with infections only.2,14 We showed that non-infectious
clinical complications were present in CVID but not in
IPH, suggesting that the latter condition might have a bet-
ter prognosis. Due to the relatively small cohort of IPH
patients, we cannot exclude the possibility that some of
them could present with or develop non-infectious clinical
complications. 
In line with the clinical differences, analysis of the earli-
er presented B-cell patterns9 revealed that defective B-cell
production and early peripheral B-cell maturation or sur-
vival defect (B-cell patterns 1 and 2, respectively) were
seen exclusively in CVID. In addition, we showed that
these two B-cell patterns are associated with non-infec-
tious disease-related clinical complications. Early defects
in B-cell development apparently tend to result in the full
CVID phenotype and more often give rise to immune
deregulation. Further analysis of B-cell patterns showed
that more than half of the CVID patients display B-cell
patterns 1-3, indicative of defects in peripheral B-cell
development before the GC stage. In contrast, the majori-
ty of IPH patients did not show abnormalities in peripher-
al B-cell distribution, suggesting a defect in post-GC (ter-
G. Driessen et al.
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Table 3. Reference values of peripheral B-cell subset absolute counts.
                                             Cord blood                 0-2 years                2-5 years                    5-10 years               10-16 years                     >16 years
                                                 n=26                        n=21                       n=23                           n=30                         n=28                              n=28
Transitional                                       164                                 222                                 87                                       36                                    22                                          12
                                                         (32-278)                        (38-551)                      (24-333)                             (11-77)                          (4-108)                                 (3-50)
Naive mature                                    362                                 992                                540                                     262                                  176                                        134
                                                        (124-821)                     (322-1991)                  (170-1691)                        (111-486)                       (87-390)                              (57-447)
CD27-IgA+                                         0.7                                    3                                   18                                       13                                     3                                            2
                                                           (0-2.5)                          (0.6-51)                       (1.6-43)                             (1.1-26)                         (0.8-21)                               (0.4-25)
CD27+IgD+IgM+                             29                                   85                                  58                                       42                                    20                                          26
                                                           (4-70)                          (23-195)                      (16-226)                             (15-88)                           (7-90)                                  (9-88)
CD27-IgG+                                         0.8                                   11                                  29                                       20                                    11                                           7
                                                            (0-7)                             (2-46)                         (7-143)                               (5-47)                            (2-47)                                  (1-46)
CD27+IgD-IgM+                                0                                     5                                    7                                         4                                      3                                            3
                                                            (0-1)                             (1-26)                          (2-34)                                (1-20)                            (1-12)                                  (1-33)
CD27+IgA+                                        0.1                                   10                                  10                                        9                                      7                                           10
                                                            (0-1)                             (3-39)                          (1-35)                                (4-25)                            (2-17)                                  (2-35)
CD27+IgG+                                       0.5                                   18                                  19                                       15                                    16                                          15
                                                            (0-2)                             (4-65)                         (45-56)                               (6-44)                            (3-34)                                  (5-59)
Median (5th and 95th percentile) in cells/μL.
minal) B-cell or a plasma-cell defect such as a differentia-
tion, a survival and/or homing defect. Thus, the identifica-
tion of B-cell patterns is useful to detect differences in
pathophysiological background and has the potential to
become clinically relevant in the follow up of CVID and
IPH, because of the association with non-infectious clini-
cal complications. 
We analyzed memory B-cell subsets in CVID and IPH
and compared these to 130 age-matched controls. We
showed that absolute numbers of memory B-cell subsets
in healthy individuals reach adult levels within two years
of age and do not substantially increase afterwards. The
observed relative increase in memory B cells mainly
reflects a reduction of transitional and naive B cells over
time. Our data are in line with previously published B-cell
subset reference values.15-19 Memory B cells were reduced
in the majority of CVID patients and mainly involved GC-
dependent maturation pathways. IPH patients less fre-
quently showed abnormalities in memory B-cell subsets,
in line with our hypothesis that most of these patients suf-
fer from plasma-cell survival or homing defects. 
CVID and IPH are two partly overlapping conditions.
IPH is similar to CVID with respect to infectious compli-
cations, but is not the same with respect to non-infectious
clinical complications, immunoglobulin levels, distribution
of B-cell patterns and memory B-cell counts. Functional
immunological studies should focus on plasma-cell differ-
entiation and homing. Clinical follow-up studies of larger
numbers of IPH patients should be performed to assess the
prognosis, facilitate the development of optimal treatment
strategies, and determine the place of IPH in current PID
classification systems. 
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